Phase I trials of targeted anticancer drugs: a need to refocus

Phase I trials of targeted anticancer drugs: a need to refocus

As cancer therapy progresses through the development of molecularly targeted drugs, the focus of Phase I trials needs to shift towards investigating end points that could guide more effective trial design, dosing and choice of tumour setting for Phase II studies.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews. Drug discovery 2012-12, Vol.11 (12), p.889-890
Hauptverfasser: Borden, Ernest C., Dowlati, Afshin
Format: Artikel
Sprache:eng
Schlagworte:
67
692/699/67/1059/602
Antimitotic agents
Antineoplastic agents
Antineoplastic Agents - adverse effects
Biomedical and Life Sciences
Biomedicine
Biotechnology
Cancer Research
Clinical trials
Clinical Trials, Phase I as Topic
comment
Humans
Medicinal Chemistry
Molecular Medicine
Neoplasms - drug therapy
Pharmacology/Toxicology
Research Design
Safety and security measures
Testing
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:As cancer therapy progresses through the development of molecularly targeted drugs, the focus of Phase I trials needs to shift towards investigating end points that could guide more effective trial design, dosing and choice of tumour setting for Phase II studies.
ISSN:1474-1776
1474-1784
DOI:10.1038/nrd3909